530

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 2804-H

Total Pages in this Submission 3

#### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an										
invention entitled:										
CD30 LIGAND										
and invented by:										
Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage and Hans-Juergen Gruss										
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:										
☐ Continuation ☑ Divisional ☐ Continuation-in-part (CIP) of prior application	n No.: <u>08/580,014</u>									
Which is a:	. No.									
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application Which is a:	n No.:									
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application	n No.:									
Enclosed are:										
Application Elements										
1. X Filing fee as calculated and transmitted as described below										
2. Specification having pages and including the following	ng:									
a. 🗷 Descriptive Title of the Invention										
b. 🗷 Cross References to Related Applications (if applicable)										
c.   Statement Regarding Federally-sponsored Research/Development (if applied)	cable)									
d.  Reference to Microfiche Appendix (if applicable)										
e. 🗷 Background of the Invention										
f. 🗵 Brief Summary of the Invention										
g.   Brief Description of the Drawings (if drawings filed)										
h. 🗵 Detailed Description										
i. 🗵 Claim(s) as Classified Below										
j. 🛮 Abstract of the Disclosure										

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 2804-H

Total Pages in this Submission

3.		Dra	awing(s) (when necessary as prescribed by 35 USC 113)									
	a.		Formal	Number of Sheets								
	b.		Informal	Number of Sheets								
4.	X	Oat	h or Declaration									
	a.		Newly executed (original or copy)									
	b.	X	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)									
	c.	X	With Power of Attorney									
	d.		DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).									
5.	X	The Box	corporation By Reference (usable if Box 4b is checked) e entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under x 4b, is considered as being part of the disclosure of the accompanying application and is hereby orporated by reference therein.									
6.		Con	mputer Program in Microfiche <i>(Appendix)</i>									
7.	X	Nuc	ucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)									
	a.	X	Paper Copy									
	b.		Computer Readable Copy (identical to computer copy)									
	C.		☐ Statement Verifying Identical Paper and Computer Readable Copy									
				Accompanying Application Parts								
8.		Ass	Assignment Papers (cover sheet & document(s))									
9.		37 (	37 CFR 3.73(B) Statement <i>(when there is an assignee)</i>									
10.		Eng	English Translation Document (if applicable)									
11.		Info	nformation Disclosure Statement/PTO-1449   Copies of IDS Citations									
12.	X	Preliminary Amendment										
13.	X	Ack	Acknowledgment postcard									
14.	×	Cer	ertificate of Mailing									
			First Class 🗵 E	Express Mail (Specify Label No.): EG646009268US								

**Application Elements (Continued)** 

# COLTABE CEASS

## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 2804-H

Total Pages in this Submission

Accompanying Application Parts (Continued)										
15.	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)									
16.	16. Additional Enclosures (please identify below):									
	Sequence Statement Under 37 CFR 1.821(e)									
	Fee Calculation and Transmittal									
				CLAIMS A	S FILED		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	
	For		#Filed	#Allowed	#Extra		Rate		Fee	
Γotal (	Claim	ns	1.3	- 20 =	0	×	\$22.00		\$0.00	
ndep.	ndep. Claims 5 - 3 = 2 x \$82.00				\$164.00					
Multip	le De	pendent C	aims (check i	f applicable)	)				\$0.00	
								BASIC FEE	\$790.00	
OTHER FEE (specify purpose)						\$0.00				
							TOTAL	FILING FEE	\$954.00	
□ A check in the amount of to cover the filling fee is enclosed. □ The Commissioner is hereby authorized to charge and credit Deposit Account No. 09-0089 as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of \$954.00 as filing fee. □ Credit any overpayment. □ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).  Signature  Kathryn A. Anderson Reg. No. 32,172  Law Department  Immunex Corporation 51 University Street  Seattle, Washington 98101  Phone (206) 587-0430  Phone (206) 587-0430										
Fax (206) 233-0644										